Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
NLRP3 mRNA is the transcript encoding the NACHT, LRR and PYD domains-containing protein 3, a key intracellular sensor of the innate immune system [UniProt]. The protein product assembles into the NLRP3 inflammasome, which activates caspase-1 to process pro-inflammatory cytokines IL-1β and IL-18 [PubMed]. Dysregulation of this pathway is linked to autoinflammatory diseases like Cryopyrin-Associated Periodic Syndromes (CAPS) and chronic conditions such as gout and Alzheimer's disease [NIH]. Therapeutic targeting of the mRNA using antisense oligonucleotides (ASOs) or siRNA aims to degrade the transcript and prevent protein synthesis [PubMed]. Clinical candidates like ION734 (IONIS-NLRP3-Rx) are designed to reduce NLRP3 expression to treat inflammatory disorders [Ionis Pharmaceuticals]. This approach potentially offers a more upstream intervention compared to blocking individual cytokines [PubMed].
Antisense-mediated mRNA degradation via RNase H or RNA interference (RNAi) to inhibit protein translation.
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on NACHT, LRR and PYD domains-containing protein 3 messenger RNA (NLRP3 mRNA).